| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Pathology and 2 Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, and Departments of 3 Surgical Oncology and 4 Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Fazlul H. Sarkar, Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 740 Hudson Webber Cancer Research Center, 110 East Warren, Detroit, MI 48201. Phone: 313-576-8327; Fax: 313-576-8389; E-mail: fsarkar{at}med.wayne.edu.
Soy isoflavone genistein exhibits growth inhibitory activity against human pancreatic cancer cell lines. We previously reported the potential of genistein to augment chemotherapeutic response of pancreatic cancer cells in vitro. In the present study, we investigated whether genistein pretreatment could be used as a novel strategy for gemcitabine-induced killing in vitro and enhanced antitumor activity in vivo using an orthotopic tumor model. We conducted our studies using paired isogenic human pancreatic cancer cell line with differences in metastatic behavior (COLO 357 and L3.6pl). In vitro studies were done to measure growth inhibition and degree of apoptotic cell death induced by either genistein alone, gemcitabine alone, or genistein followed by gemcitabine. Our results show that pretreatment of cells with genistein for 24 hours followed by gemcitabine resulted in 60% to 80% growth inhibition compared with 25% to 30% when gemcitabine was used alone. The overall growth inhibition was directly correlated with apoptotic cell death irrespective of the metastatic potential of cells. Several genes that are known to inhibit apoptosis and contribute to chemoresistance such as nuclear factor-
B (NF-B) and Akt were assessed to investigate the basis for the observed chemosensitizing effects of genistein. Genistein potentiated the gemcitabine-induced killing by down-regulation of NF-B and Akt. In contrast, Akt and NF-B were found to be up-regulated when pancreatic cancer cells were exposed to gemcitabine alone, suggesting the potential mechanism of acquired chemoresistance. In addition to in vitro results, we show here for the first time, that genistein in combination with gemcitabine is much more effective as an antitumor agent compared with either agent alone in our orthotopic tumor model. But most importantly, our data also showed that a specific target, such as NF-B, was inactivated in genistein-treated animal tumors and that gemcitabine-induced activation of NF-B was completely inhibited in animal tumors treated with genistein and gemcitabine. These results provide strong molecular in vivo evidence in support of our hypothesis that inactivation of NF-B signaling pathway by genistein could also abrogate gemcitabine-induced activation of NF-B resulting in the chemosensitization of pancreatic tumors to gemcitabine, which is likely to be an important and novel strategy for the treatment of pancreatic cancer.
This article has been cited by other articles:
|
|
 |
|
  T. UWAGAWA, P. J. CHIAO, T. GOCHO, S. HIROHARA, T. MISAWA, and K. YANAGA Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF-{kappa}B Activation Anticancer Res, August 1, 2009; 29(8): 3173 - 3178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Banerjee, Z. Wang, D. Kong, and F. H. Sarkar 3,3'-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer Cancer Res., July 1, 2009; 69(13): 5592 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Banerjee, A. O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F. H. Sarkar, and R. M. Mohammad Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer Cancer Res., July 1, 2009; 69(13): 5575 - 5583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Uwagawa, T. Misawa, T. Sakamoto, R. Ito, T. Gocho, H. Shiba, S. Wakiyama, S. Hirohara, S. Sadaoka, and K. Yanaga A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer Ann. Onc., February 1, 2009; 20(2): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Pan, T. Arumugam, T. Yamamoto, P. A. Levin, V. Ramachandran, B. Ji, G. Lopez-Berestein, P. E. Vivas-Mejia, A. K. Sood, D. J. McConkey, et al. Nuclear Factor-{kappa}B p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells Clin. Cancer Res., December 15, 2008; 14(24): 8143 - 8151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Alschuler and D. Rubin Integrative Tumor Board: Pancreatic Cancer Naturopathic Medicine Integr Cancer Ther, June 1, 2008; 7(2): 105 - 108. [PDF]
|
|
|
|
 |
|
 T. L. Johnson, M. B. Lai, J. C. K. Lai, and A. Bhushan Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A Evid. Based Complement. Altern. Med., February 29, 2008; (2008) nen011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane, J. Gelovani, and B. B. Aggarwal Curcumin Potentiates Antitumor Activity of Gemcitabine in an Orthotopic Model of Pancreatic Cancer through Suppression of Proliferation, Angiogenesis, and Inhibition of Nuclear Factor-{kappa}B-Regulated Gene Products Cancer Res., April 15, 2007; 67(8): 3853 - 3861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Raffoul, S. Banerjee, V. Singh-Gupta, Z. E. Knoll, A. Fite, H. Zhang, J. Abrams, F. H. Sarkar, and G. G. Hillman Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo Cancer Res., March 1, 2007; 67(5): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo Clin. Cancer Res., March 1, 2007; 13(5): 1611 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. El-Rayes, S. Ali, I. F. Ali, P. A. Philip, J. Abbruzzese, and F. H. Sarkar Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-{kappa}B Cancer Res., November 1, 2006; 66(21): 10553 - 10559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kaczor Naturopathy Integr Cancer Ther, June 1, 2006; 5(2): 140 - 147. [PDF]
|
|
|
|
|
|
Y. Li, O. Kucuk, M. Hussain, J. Abrams, M. L. Cher, and F. H. Sarkar Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer. Cancer Res., May 1, 2006; 66(9): 4816 - 4825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Sarkar and Y. Li Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res., April 1, 2006; 66(7): 3347 - 3350. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
